Sales of Pfizer's male impotence drug Viagra (sildenafil) are continuingto set records and are likely to reach $1 billion by March 1999, according to IMS Health. The first two-month sales of Viagra, at $182.2 million, were almost double the total revenues combined of the five leading drug launches of 1997 over the same period.
Myron Holubiak, general manager of the consulting arm of IMS, estimated that revenues will continue to soar despite lower than usual third-party coverage for the drug in the USA - 40% for Viagra versus 76% for all prescription drugs. "It seems that third-party pay organizations do not place as much value on sexuality as a part of health status as do their members or beneficiaries," said Mr Holubiak, adding that a key barometer to measure market demand and acceptance of the drug will be the refill rate of prescriptions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze